Maravai LifeSciences (MRVI) Stock Price, News & Analysis

Company Overview

Maravai LifeSciences Holdings, Inc. is a life sciences company that provides products and services used in the development and manufacture of biopharmaceuticals, vaccines, diagnostics and other advanced biological products. The company serves research, pharmaceutical, biotechnology and healthcare customers involved in nucleic acid production, biologics development and quality testing.

Maravai’s Nucleic Acid Production segment, which includes TriLink BioTechnologies, supplies specialized messenger RNA and other nucleic acid products, raw materials and related manufacturing services. These offerings support research and development as well as commercial applications such as mRNA-based medicines, vaccines, gene therapies and diagnostic products.

Through its Biologics Safety Testing segment, Maravai provides analytical services, reagents and testing products used to evaluate the safety, quality and purity of biologic products and their manufacturing processes. The company’s portfolio includes products and services for detecting contaminants and characterizing biological materials. Maravai was founded in 2014 and is headquartered in San Diego, California, serving customers in the United States and international markets through its operating companies and commercial relationships.

Key Stats

• Today's Range: $6.51 to $6.99
• 50-Day Range: $5.68 to $9.00
• 52-Week Range: $2.55 to $9.42
• Volume: 1.08 million shs
• Average Volume: 2.49 million shs
• Market Capitalization: $1.83 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.38
• Consensus Rating: Moderate Buy

Maravai LifeSciences Stock Analysis - MarketRank™

Maravai LifeSciences scored higher than 30% of companies evaluated by MarketBeat, and ranked 755th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Maravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Maravai LifeSciences is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Maravai LifeSciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.20) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Maravai LifeSciences is -13.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Maravai LifeSciences is -13.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Maravai LifeSciences has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.46% of the float of Maravai LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Maravai LifeSciences has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Maravai LifeSciences has recently increased by 11.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Maravai LifeSciences does not currently pay a dividend.

Dividend Growth

Maravai LifeSciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.45

News Sentiment

Maravai LifeSciences has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Maravai LifeSciences this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

1 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.49% of the stock of Maravai LifeSciences is held by insiders.

Percentage Held by Institutions

50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:MRVI
• CIK: 1823239
• Web: www.maravai.com
• Phone: 858-546-0004
• Fax: N/A
• Employees: 415
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Maravai LifeSciences: $7.38
• High Price Target: $9.00
• Low Price Target: $6.00
• Potential Upside/Downside: +7.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.77 million
• Net Margins: -37.07%
• Pretax Margin: -65.38%
• Return on Equity: -15.70%
• Return on Assets: -8.17%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 4.05
• Quick Ratio: 2.98

Sales & Book Value

• Annual Sales: $208.78 million
• Price / Sales: 8.53
• Cash Flow: $0.44 per share
• Price / Cash Flow: 15.60
• Book Value: $1.46 per share
• Price / Book: 4.70

Miscellaneous

• Outstanding Shares: 259,674,000
• Free Float: 253,208,000
• Market Cap: $1.78 billion
• Optionable: Optionable
• Beta: 0.54